{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:37:00Z","timestamp":1790977020802,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.resinv.2024.09.013","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T09:17:51Z","timestamp":1728638271000},"page":"1157-1160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic effects of an ALK inhibitor, brigatinib, on lung large cell neuroendocrine carcinoma with EML4-ALK fusion"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3279-0699","authenticated-orcid":false,"given":"Takayuki","family":"Suetsugu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Masada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Kozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahoru","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-992X","authenticated-orcid":false,"given":"Hajime","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-4813","authenticated-orcid":false,"given":"Kazuhiro","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-3812","authenticated-orcid":false,"given":"Hiromasa","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2024.09.013_bib1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.09.013_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.thorsurg.2021.05.005","article-title":"Neuroendocrine tumors of the lung","volume":"31","author":"Randhawa","year":"2021","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.resinv.2024.09.013_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.resinv.2024.09.013_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.911294","article-title":"Targeting ALK in neuroendocrine tumors of the lung","volume":"12","author":"Akhoundova","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.resinv.2024.09.013_bib5","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.09.013_bib6","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jtho.2018.02.002","article-title":"New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management","volume":"13","author":"Derks","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2024.09.013_bib7","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-15-2946","article-title":"Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets","volume":"22","author":"Rekhtman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2024.09.013_bib8","article-title":"Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.resinv.2024.09.013_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103400","article-title":"Treatment of brain metastases in ALK-positive non-small cell lung cancer","volume":"165","author":"Ceddia","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.resinv.2024.09.013_bib10","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/1878-0261.13446","article-title":"EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries","volume":"17","author":"Elshatlawy","year":"2023","journal-title":"Mol Oncol"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:32:33Z","timestamp":1739345553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534524001527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2212534524001527"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2024.09.013","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effects of an ALK inhibitor, brigatinib, on lung large cell neuroendocrine carcinoma with EML4-ALK fusion","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2024.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}]}}